Contineum Therapeutics, Inc. Stock-Based Compensation
Contineum Therapeutics, Inc. (CTNM) reported Stock-Based Compensation of $7.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-07-30
- Contineum Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $3.84M, a 58.81% increase year-over-year.
- Contineum Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $3.82M, a 48.81% increase year-over-year.
- Contineum Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.48M, a 10.26% increase year-over-year.
- Contineum Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.57M, a 12.13% increase year-over-year.
- Contineum Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $10.04M, a 47.53% increase from fiscal 2024.
- Contineum Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $6.80M, a 206.62% increase from fiscal 2023.
- Contineum Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $2.22M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $7.66M 10-Q · filed 2026-07-30 | $10.14M derived: sum of 3 quarters · filed 2026-07-30 | $12.71M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $3.82M 10-Q · filed 2026-05-05 | $6.30M derived: sum of 2 quarters · filed 2026-05-05 | $8.87M derived: sum of 3 quarters · filed 2026-05-05 | $11.29M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $5.05M derived: sum of 2 quarters · filed 2026-03-05 | $7.47M derived: sum of 3 quarters · filed 2026-07-30 | $10.04M 10-K · filed 2026-03-05 |
| 2025-09-30 | $2.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $4.99M derived: sum of 2 quarters · filed 2026-07-30 | $7.56M 10-Q · filed 2025-10-30 | $9.81M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $2.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $4.99M 10-Q · filed 2026-07-30 | $7.24M derived: sum of 3 quarters · filed 2026-07-30 | $9.53M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $2.57M 10-Q · filed 2026-05-05 | $4.82M derived: sum of 2 quarters · filed 2026-05-05 | $7.11M derived: sum of 3 quarters · filed 2026-05-05 | $8.61M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $4.54M derived: sum of 2 quarters · filed 2026-03-05 | $6.04M derived: sum of 3 quarters · filed 2026-03-05 | $6.80M 10-K · filed 2026-03-05 |
| 2024-09-30 | $2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $3.79M derived: sum of 2 quarters · filed 2025-10-30 | $4.55M 10-Q · filed 2025-10-30 | $5.31M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $1.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $2.26M 10-Q · filed 2025-08-05 | $3.02M derived: sum of 3 quarters · filed 2025-08-05 | $3.50M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $768.00K 10-Q · filed 2025-05-14 | $1.53M derived: sum of 2 quarters · filed 2025-05-14 | $2.00M derived: sum of 3 quarters · filed 2025-05-14 | $2.49M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $759.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $1.24M derived: sum of 2 quarters · filed 2025-03-06 | $1.73M derived: sum of 3 quarters · filed 2025-03-06 | $2.22M 10-K · filed 2025-03-06 |
| 2023-09-30 | $477.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $966.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.46M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $489.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $983.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $494.00K 10-Q · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |